Global Biosimilars Market Size & Outlook, 2020-2027
Global biosimilars market, 2016-2027 (US$M)
Related Markets
Global biosimilars market highlights
- The global biosimilars market generated a revenue of USD 13,216.7 million in 2020 and is expected to reach USD 46,252.5 million by 2027.
- The market is expected to grow at a CAGR (2021 - 2027) of 19.6% by 2027.
- In terms of segment, recombinant non-glycosylated proteins accounted for a revenue of USD 7,163.1 million in 2020.
- Recombinant Glycosylated Proteins is the most lucrative product segment registering the fastest growth during the forecast period.
- In terms of region, Europe was the largest revenue generating market in 2020.
- Country-wise, Germany is expected to register the highest CAGR from 2021 to 2027.
Global data book summary
| Market revenue in 2020 | USD 13,216.7 million |
| Market revenue in 2027 | USD 46,252.5 million |
| Growth rate | 19.6% (CAGR from 2020 to 2027) |
| Largest segment | Recombinant non-glycosylated proteins |
| Fastest growing segment | Recombinant Glycosylated Proteins |
| Historical data covered | 2016 - 2019 |
| Base year for estimation | 2020 |
| Forecast period covered | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins |
Other key industry trends
- In terms of revenue, the North America accounted for 25.6% of the global biosimilars market in 2020.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2027.
- By country, Germany is the fastest growing regional market and is projected to reach USD 3,347.3 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biosimilars Market Scope
Biosimilars Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Global biosimilars market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimilars market will help companies and investors design strategic landscapes.
Recombinant non-glycosylated proteins was the largest segment with a revenue share of 54.2% in 2020. Horizon Databook has segmented the Global biosimilars market based on recombinant non-glycosylated proteins, recombinant glycosylated proteins covering the revenue growth of each sub-segment from 2016 to 2027.
- Global Biosimilars Product Outlook (Revenue, USD Million, 2016-2027)
- Recombinant Non-Glycosylated Proteins
- Human Growth Hormone
- Granulocyte Colony-Stimulating Factor
- Insulin
- Recombinant Glycosylated Proteins
- Erythropoietin
- Monoclonal Antibodies
- Follitropin
- Recombinant Non-Glycosylated Proteins
- Global Biosimilars Application Outlook (Revenue, USD Million, 2016-2027)
- Oncology
- Blood Disorders
- Growth Hormonal Deficiency
- Rheumatoid Arthritis
- Chronic and Autoimmune Disorders
- Others
- Global Biosimilars Manufacturing Type Outlook (Revenue, USD Million, 2016-2027)
- In House Manufacturing
- Contract Manufacturing
Reasons to subscribe to Global biosimilars market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global biosimilars market databook
-
Our clientele includes a mix of biosimilars market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global biosimilars market , including forecasts for subscribers. This global databook contains high-level insights into Global biosimilars market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
Global biosimilars market size, by regions, 2016-2027 (US$M)
Top 10 countries: Biosimilars market size, 2020 (US$M)
Global biosimilars market share, by product, 2020 & 2027 (%, US$M)
Biosimilars market: Opportunity assessment by country
Global biosimilars market, by region, 2020 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
